[Bekijk de online versie in uw browser]

Radboudumc
university medical center

Newsletter

European Reference Network | Genetic Tumour Risk Syndromes (ERN GENTURIS)

November 2021 | www.genturis.eu

Webinar 'NF1 from the paediatric perspective'

Wednesday 10 November 2021, 16:00-17:00 CET

Dr. Rianne Oostenbrink, Erasmus MC, Rotterdam

Dr. Rianne Oostenbrink is an Associate Professor in the Department of General Pediatrics, at Erasmus MC in Rotterdam, The Netherlands, and works as a general pediatrician in the outpatient clinic and pediatric emergency department. She is the coordinator of the ENCORE-NF1 expertise centre at Erasmus MC, a collaborative, multidisciplinary team for inherited neuro-cognitive developmental diseases, which leads the national NF1 clinical network in the Netherlands.

This webinar will address the manifestations of NF1 in children. Children differ from adults with NF1 by either not having the full criteria present, but also being at risk for a difference in type of manifestations. Next, the impact of NF1 on cognitive and social development in children is substantial with specific needs for support. The webinar will discuss the multidisciplinary care for children with NF1.

If you would like to attend this webinar, please register here:
https://register.gotowebinar.com/register/2067838741891673868

Webinar 'Somatic Mosaicism in Tumour Genetics'

Wednesday 24 November 2021, 16:00-17:00 CET

Prof. dr. Stefan Aretz,
University of Bonn, Germany

Prof. Stefan Aretz is deputy head at the Institute of Human Genetics, University of Bonn, Germany. He is professor of genetics of familial tumour syndromes.

In the NGS era, somatic (postzygotic) mutational mosaicism in genes underlying tumour predisposition syndromes is more frequently observed than previously thought and its importance is increasingly recognized. Confirmation of a mosaic mutation has major consequences for patient care and genetic counselling in families. The webinar will address relevant conditions prone to mosaicism as well as low-level mosaicism in blood resulting from circulating tumour DNA, and discuss diagnostic challenges and clinical implications.

If you would like to attend this webinar, please register here:
https://register.gotowebinar.com/register/7249411532286919438

EJMG ERN GENTURIS special issue

The first four papers of the EJMG ERN GENTURIS special issue are now online! See https://www.sciencedirect.com/journal/european-journal-of-medical-genetics/special-issue/10PFC6MB478

Endorsed Guidelines

ERN GENTURIS recently endorsed existing guidelines on neurofibromatosis type 1 and Legius syndrome, Lynch syndrome, polyposis syndromes, and Peutz-Jeghers

syndrome. For more information on these guidelines, see https://www.genturis.eu/l=eng/Clinical-practice-guidelines.html

Apply for the ERN Research Mobility Fellowship until November 28th

The 4th call of the ERN Research Mobility Fellowships is open until 28 November. For more information see https://www.ejpraretdiseases.org/ern-research-mobility-fellowship/

Save the date: ERN GENTURIS 5-year anniversary conference on 10-11 Feb 2022

On 10-11 February 2022, ERN GENTURIS will celebrate its 5-year anniversary with a free online conference. The conference will feature updates on the ERN GENTURIS tumour predisposition syndromes, reports on special ERN GENTURIS projects and patient perspectives. It will also include a half-day introductory educational session specially aimed at general practitioners.

More details on the conference program and registration will be available soon via https://www.genturis.eu/l=eng/News-and-events/ERN-GENTURIS-conference-Feb-2022.html

Upcoming webinar:

Tuesday 7 December: Eric Legius (KU Leuven) –
Legius syndrome and its link with Neurofibromatosis type 1

For more information on webinars and registration, visit www.genturis.eu

ERN GENTURIS Coordinating Center:

Radboud university medical center
The Netherlands

genturis@radboudumc.nl
https://www.genturis.eu

How to unsubscribe?

You received this newsletter because you are a contact of ERN GENTURIS. If you no longer wish to receive newsletters, please unsubscribe.